Royalty Pharma Stock News

January Buffett Dividend Dogs Show 3 Dandy Dynamutts

Royalty Pharma (RPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ: RPRX ) today announced that its board of directors has declared a dividend for the first quarter of 2022 of $0.19 per Class A share, reflecting a 12% increase in the company''s quarterly dividend over the previous quarter''s dividend. The dividend will be paid on March 15, 2022, to shareholders of record at the close of business on February 18, 2022. About Full story available on Benzinga.com

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET.

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8

The founder-led business is a profitable, cash flow positive business that is trading at a slight discount now. Six quarters after its IPO, the company has demonstrated a strong record of meeting/beat

This Buffett holdings list from Kiplinger first appeared 9/16/21 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 12/15/21 YCharts data. 28 of 43 c

Should investors consider these healthcare dividend stocks amid the current market volatility?

AbbVie and Royalty Pharma should be on every dividend investor's radar right now.

Highland Capital Management LLC acquired a new position in Royalty Pharma plc (NASDAQ:RPRX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 56,854 shares of the biopharmaceutical companys stock, valued at approximately $2,055,000. Several other institutional investors have also recently modified their holdings []

Brown University grew its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 62.9% during the 3rd quarter, Holdings Channel.com reports. The fund owned 621,759 shares of the biopharmaceutical companys stock after acquiring an additional 240,000 shares during the period. Royalty Pharma accounts for about 3.0% of Brown Universitys portfolio, making the stock its 3rd largest position. []

Revance Therapeutics (NASDAQ:RVNC) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Earnings and Valuation This table compares Revance Therapeutics and Royalty Pharmas revenue, earnings per share and []

Revance Therapeutics (NASDAQ:RVNC) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Valuation and Earnings This table compares Revance Therapeutics and Royalty Pharma’s revenue, earnings per share (EPS) […]

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual C